US 8507663
Compositions and methods for inhibiting expression of CD274/PD-L1 gene
granted A61KA61K31/713A61P
Quick answer
US patent 8507663 (Compositions and methods for inhibiting expression of CD274/PD-L1 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Aug 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K31/713, A61P, A61P31/00, A61P31/04